Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNAs as Diagnostic Biomarkers and Predictors of Antidepressant Response in Major Depressive Disorder: A Systematic Review.
Carneiro BA, Franco Guerreiro-Costa LN, Lins-Silva D, Faria Guimaraes D, Souza LS, Leal GC, Caliman-Fontes AT, Beanes G, Costa RDS, Quarantini LC. Carneiro BA, et al. Among authors: caliman fontes at. Cureus. 2024 Mar 25;16(3):e56910. doi: 10.7759/cureus.56910. eCollection 2024 Mar. Cureus. 2024. PMID: 38665721 Free PMC article. Review.
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
Echegaray MVF, Mello RP, Magnavita GM, Leal GC, Correia-Melo FS, Jesus-Nunes AP, Vieira F, Bandeira ID, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Marback RF, Souza-Marques B, Lins-Silva DH, Santos-Lima C, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Echegaray MVF, et al. Among authors: caliman fontes at. Trends Psychiatry Psychother. 2023 Sep 17. doi: 10.47626/2237-6089-2022-0593. Online ahead of print. Trends Psychiatry Psychother. 2023. PMID: 37717263 Free article.
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.
Bandeira ID, Leal GC, Correia-Melo FS, Souza-Marques B, Silva SS, Lins-Silva DH, Mello RP, Vieira F, Dorea-Bandeira I, Faria-Guimarães D, Carneiro B, Caliman-Fontes AT, Kapczinski F, Miranda-Scippa Â, Lacerda ALT, Quarantini LC. Bandeira ID, et al. Among authors: caliman fontes at. J Psychiatr Res. 2023 Aug;164:229-234. doi: 10.1016/j.jpsychires.2023.06.028. Epub 2023 Jun 23. J Psychiatr Res. 2023. PMID: 37385001 Clinical Trial.
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.
Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. Leal GC, et al. Among authors: caliman fontes at. J Affect Disord. 2023 Jun 1;330:7-15. doi: 10.1016/j.jad.2023.02.151. Epub 2023 Mar 4. J Affect Disord. 2023. PMID: 36871913 Clinical Trial.
Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
Beanes G, Caliman-Fontes AT, Souza-Marques B, Silva HDS, Leal GC, Carneiro BA, Guerreiro-Costa LNF, Figueiredo AV, Figueiredo CAV, Lacerda ALT, Costa RDS, Quarantini LC. Beanes G, et al. Among authors: caliman fontes at. Clin Neuropharmacol. 2022 Nov-Dec 01;45(6):151-156. doi: 10.1097/WNF.0000000000000517. Epub 2022 Sep 11. Clin Neuropharmacol. 2022. PMID: 36093918 Clinical Trial.
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP, Leal GC, Correia-Melo FS, Vieira F, Mello RP, Caliman-Fontes AT, Echegaray MVF, Marback RF, Guerreiro-Costa LNF, Souza-Marques B, Santos-Lima C, Souza LS, Bandeira ID, Kapczinski F, Lacerda ALT, Quarantini LC. Jesus-Nunes AP, et al. Among authors: caliman fontes at. Hum Psychopharmacol. 2022 Jul;37(4):e2836. doi: 10.1002/hup.2836. Epub 2022 Feb 18. Hum Psychopharmacol. 2022. PMID: 35179810 Clinical Trial.
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixão CS, Carvalho MS, Jesus-Nunes AP, Vieira F, Magnavita G, Bandeira ID, Mello RP, Beanes G, Silva SS, Echegaray M, Carvalho LP, Machado P, Sampaio AS, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Caliman-Fontes AT, et al. Trends Psychiatry Psychother. 2023;45:e20210298. doi: 10.47626/2237-6089-2021-0298. Epub 2023 Mar 7. Trends Psychiatry Psychother. 2023. PMID: 34904800 Free PMC article. Clinical Trial.
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Mello RP, Echegaray MVF, Jesus-Nunes AP, Leal GC, Magnavita GM, Vieira F, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Souza-Marques B, Bandeira ID, Santos-Lima C, Marback RF, Correia-Melo FS, Lacerda ALT, Quarantini LC. Mello RP, et al. Among authors: caliman fontes at. J Psychiatr Res. 2021 Jun;138:576-583. doi: 10.1016/j.jpsychires.2021.05.014. Epub 2021 May 8. J Psychiatr Res. 2021. PMID: 33991996 Clinical Trial.
Impact of Delirium and Its Motor Subtypes on Stroke Outcomes.
Fialho Silva IT, Assis Lopes P, Timotio Almeida T, Ramos SC, Caliman Fontes AT, Guimarães Silva D, Martins Soares C, Oliveira Carneiro L, Souza IFB, Ferreira Abreu F, Nascimento Silva G, Mascarenhas de Souza L, Brito Pinheiro T, de Souza E Silva FN, de Santana JP, Kelly Silva B, Almeida Souza D, Silva Macedo S, Almeida Ismael LS, Pereira de Jesus PA. Fialho Silva IT, et al. Among authors: caliman fontes at. Stroke. 2021 Apr;52(4):1322-1329. doi: 10.1161/STROKEAHA.120.026425. Epub 2021 Mar 15. Stroke. 2021. PMID: 33719516
13 results